Search results
Two Biosimilars Approved in Europe for Autoimmune Disorders
Medscape· 7 days agoThe drugs are intended to treat several types of arthritis, psoriasis, COVID-19, and Crohn's...
Janssen-Cilag seeks expanded EMA approval for TREMFYA
Pharmaceutical Technology via Yahoo Finance· 6 hours agoTreatment with guselkumab also offered statistically significant and clinically meaningful...
FDA OKs High-Concentration of Adalimumab Biosimilar Cyltezo
Medscape· 12 hours agoUnlike the low-concentration formulation of adalimumab-adbm, launched July 1, 2023, this high-concentration version has not yet been granted an interchangeability designation.
What Is Psoriatic Arthritis? 3 MDs Weigh In
PopSugar· 1 day agoPsoriasis affects about three percent of American adults, but the disorder can raise the risk of having more than skin scales and plaques. About 30 percent ...
These Pictures Will Help You Identify the Most Common Skin Rashes
Prevention via Yahoo News· 6 days agoFrom eczema to allergic reactions to bug bites, here’s what common skin rashes look like in photos,...
SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Ventyx...
WTNH-TV New Haven· 4 days agoPomerantz LLP announces that a class action lawsuit has been filed against Ventyx Biosciences, Inc. ("Ventyx" or the "Company") (NASDAQ: VTYX) and certain officers. The class action, filed in ...
AbbVie's newer drugs are offsetting losses of the world's once best-selling medication
Quartz· 6 days agoSales of the pharma giant's newer drugs are offsetting its Humira losses.
AbbVie (NYSE:ABBV) Price Target Cut to $187.00
ETF DAILY NEWS· 1 day agoAbbVie (NYSE:ABBV – Get Free Report) had its target price cut by equities researchers at Barclays from $195.00 to $187.00 in a research report issued on Monday, Benzinga reports. Barclays‘s ...
AbbVie (NYSE:ABBV) Shares Down 0.5% After Analyst Downgrade
ETF DAILY NEWS· 2 days agoAbbVie Inc. (NYSE:ABBV – Get Free Report) shares fell 0.5% on Monday after Barclays lowered their price target on the stock from $195.00 to $187.00. AbbVie traded as low as $158.56 and last ...
AbbVie (NYSE:ABBV) Price Target Cut to $180.00 by Analysts at BMO Capital Markets
ETF DAILY NEWS· 2 days agoAbbVie (NYSE:ABBV – Free Report) had its price objective cut by BMO Capital Markets from $195.00 to $180.00 in a report published on Monday morning, Benzinga reports. A number of other analysts ...
